Mural Oncology's stock plummeted 57% after halting the Phase 3 ARTISTRY-7 trial for nemvaleukin alfa. Click here to read an ...

The company’s Phase III trial of nemvaleukin alfa alongside Keytruda saw just a 0.3 month gain in overall survival over other ...

Mural Oncology (NASDAQ:MURA – Get Free Report) was downgraded by stock analysts at Raymond James from a “strong-buy” rating ...

Mural Oncology (NASDAQ:MURA – Get Free Report) had its target price lowered by equities researchers at HC Wainwright from $18 ...

Mural Oncology ends nemvaleukin development for ovarian cancer after ARTISTRY-7 trial misses survival goals. Phase 2 trials ...

Indio has a new mural that's meaning goes beyond creative art. Artist Patrick Barwinski created the "Desi Memorial Mural," in ...

Mural Oncology (NASDAQ:MURA) stock plummets 47% as the company, a spinoff of Alkermes (ALKS) halts a Phase 3 trial for its ...

Raymond James downgraded Mural Oncology (MURA) to Outperform from Strong Buy with a price target of $6, down from $18, after the company ...

Morgan Stanley downgraded Mural Oncology (MURA) to Equal Weight from Overweight and removed the firm’s prior $13 price target after removing ...

Mural Oncology said that it won't continue developing its ovarian cancer drug candidate Nemvaleukin to be used in conjunction with Merck's Keytruda after results showed no statistical improvement in ...

Fintel reports that on March 25, 2025, Jones Trading downgraded their outlook for Mural Oncology (NasdaqGM:MURA) from Buy to Hold. Analyst Price Forecast Suggests 332.77% Upside As of March 19, 2025, ...

WALTHAM, Mass - Mural Oncology plc (NASDAQ:MURA), a clinical-stage biopharmaceutical company valued at approximately $66 million, has announced the discontinuation of its phase 3 ARTISTRY-7 trial ...